Vitreous is very stable in highly acidic and alkaline conditions

Article

Vitreous has a greater buffering capacity than sodium chloride (0.9% NaCl), suggesting that it is able to remain more stable when acidic or alkaline pharmaceuticals are injected in microlitre amounts.

Vitreous has a greater buffering capacity than sodium chloride (0.9% NaCl), suggesting that it is able to remain more stable when acidic or alkaline pharmaceuticals are injected in microlitre amounts, according to a study published in the January issue of Retina.

Mandi Conway and colleagues from the University of Arizona College of Medicine, Department of Ophthalmology and Vision Science, Tucson, USA carried out a study to measure the buffering capacity of bovine vitreous to hydrogen chloride (HC1), sodium hydroxide (NaOH) and triamcinolone acetonide.

Vitreous was dissected from 10 bovine globes, homogenized and divided into 5 mL aliquots. The carbonate/bicarbonate buffer of the vitreous was maintained by performing all subsequent titrations under an atmosphere of 5% CO2/95% air. The pH was monitored during the addition of 0.1 N HC1, 0.1 N NaOH or 40 mg/mL triamcinolone acetonide to the vitreous sample; 0.9% NaC1 was used as a control.

The researchers found that the buffering capacity of bovine vitreous to HC1 was 10 times greater than that of 0.9% NaC1 and that the buffering capacity of vitreous to NaOH was four times greater than that of 0.9% NaC1. It was also discovered that bovine vitreous was able to resist pH changes from addition of triamcinolone acetonide at levels 20 time greater than commonly injected intravitreally.

The results of this study indicate that vitreous is more capable of remaining stable when acidic or alkaline pharmaceuticals are injected into it.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.